Overview
- Peptide (C)KYLYEDEG(S)WTRNS, corresponding to amino acid residues 288-301 of rat GLP1R (Accession P32301). 2nd extracellular loop.
- Rat pancreas lysate, rat pancreatic islet cell line RIN-5F lysate, mouse preadipocyte 3T3-L1 cell line lysate and human pancreatic carcinoma PANC-1 cell line lysate (1:200).
Western blot analysis of rat pancreas lysate (lanes 1 and 5), mouse preadipocyte 3T3-L1 lysate (lanes 2 and 6), rat pancreatic islet cell line RIN-5F lysate (lanes 3 and 7) and human pancreatic carcinoma PANC-1 lysate (lanes 4 and 8):1-4. Anti-GLP1R (extracellular) Antibody (#AGR-021), (1:200).
5-8. Anti-GLP1R (extracellular) Antibody, preincubated with GLP1R (extracellular) Blocking Peptide (#BLP-GR021).
- Rat pancreas sections (paraffin-embedded), (1:100).
- Live intact rat pancreatic islet cell line RIN-5F cells (1:100).
Glucagon-like peptide 1 (GLP-1) is a hormone secreted by the intestine following a meal1. This hormone is known to enhance the secretion of insulin, important glucose blood level regulation2,3. In pancreatic β-cells, other than stimulating insulin secretion, GLP-1 action is also important for β-cell mass expansion2.
GLP-1 exerts its biological functions through Glucagon-like peptide 1 receptor (GLP-1 receptor), a member of the G-protein coupled receptor superfamily. Like all members, this receptor spans the membrane seven times. GLP-1 receptor couples with Gs, thereby stimulating adenylate cyclase, consequently leading to an increase in cAMP2.
The receptor is expressed in various tissues, namely the pancreas, adipose tissue, muscle, heart, gastrointestinal tract and liver. GLP-1 receptor is also found in the central nervous system where it provides a neuroprotective effect4.
The glucagon-like peptide 1 system may serve as a therapeutic treatment in diabetes mellitus, in order to maintain β-cell mass expansion2. In addition, the receptor may serve as a therapy target in various neurodegenerative diseases like Alzheimer’s and Parkinson’s disease4.
